In patients with mild renal impairment, as per the European labeling, dose adjustment for GLP-1 RAs is not needed, but some cannot be used or are not recommended in patients with severe renal impairment and end-stage disease [12], with exceptions such as dulaglutide, liraglutide, and semaglutide, which can be used in severe renal impairment but not end-stage renal disease
Compounding organizations have pushed back, filing lawsuits challenging the FDAs decisions to curtain compounding
semaglutide doesnt compete with most drugs for liver metabolism Sulfonylureas (glipizide, glimepiride, glyburide): Same hypoglycemia risk
It is associated with appetite regulation and metabolic control through its multi-receptor activity and is commonly placed in the weight-loss and metabolic wellness segment
Also be aware of long-term safety questions and make sure your provider is monitoring you carefully